Alterations in Cell Cycle Genes in Early Stage Lung Adenocarcinoma Identified by Expression Profiling
暂无分享,去创建一个
Sunil Singhal | Mary E Putt | Robert Kruklitis | S. Singhal | M. Putt | L. Kaiser | S. Albelda | L. Litzky | Larry R Kaiser | Steven M Albelda | Kunjlata M Amin | Peter DeLong | Michael E Friscia | Leslie A Litzky | M. Friscia | P. Delong | R. Kruklitis | Kunjilata Amin
[1] M. Tschan,et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. , 1998, Oncogene.
[2] Q. Zhan,et al. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. , 2002, Molecular immunology.
[3] Q. Zhan,et al. The mismatch repair system is required for S-phase checkpoint activation , 2003, Nature Genetics.
[4] J. H. Lee,et al. ©1999 Cancer Research Campaign Article no. bjoc.1999.0661 , 2022 .
[5] E. Carosella,et al. Human CDK10 gene isoforms. , 2000, Biochemical and biophysical research communications.
[6] Margaret Kasten,et al. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.
[7] J. Minna,et al. Molecular genetics of lung cancer. , 1988, Annual review of medicine.
[8] K. Nagashima,et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. , 2001, Lung cancer.
[9] Pierre Baldi,et al. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..
[10] C. Markopoulos,et al. The prognostic value of alpha-thymosins in breast cancer. , 1998, Anticancer research.
[11] Sunil Singhal,et al. Gene expression profiling of malignant mesothelioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] Kazushige Yamaguchi,et al. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. Monden,et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. , 2002, Liver.
[14] H. Kiyokawa,et al. The Cell Cycle-Regulatory CDC25A Phosphatase Inhibits Apoptosis Signal-Regulating Kinase 1 , 2001, Molecular and Cellular Biology.
[15] H. Wada,et al. Clinical significance of p21 expression in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. H. Kim,et al. Amplified CDK2 and cdc2 activities in primary colorectal carcinoma , 1999, Cancer.
[17] J. Bockaert,et al. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors , 1999, Oncogene.
[18] N. Mailand,et al. Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.
[19] S. Elledge,et al. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. , 2001, Cancer research.
[20] J. Ritter. Tumors of the Lower Respiratory Tract: Atlas of Tumor Pathology , 1996 .
[21] F. Kaye,et al. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer , 2002, Oncogene.
[22] J. Jen,et al. Serial analysis of gene expression in non-small cell lung cancer. , 1998, Cancer research.
[23] R. Figlin,et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. , 1993, Oncogene.
[24] J. Forteza,et al. Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. , 1993, European journal of cancer.
[25] Masakazu Ueda,et al. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas , 2002, Hepatology.
[26] A. Baldi,et al. Expression of p21 in non small cell lung cancer relationship with PCNA. , 2000, Anticancer research.
[27] Anu Gupta,et al. Study of the G2/M cell cycle checkpoint in irradiated mammary epithelial cells overexpressing Cul-4A gene. , 2002, International journal of radiation oncology, biology, physics.
[28] Y. Inayama,et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. , 2001, Lung cancer.
[29] E. Lam,et al. DP and E2F proteins: coordinating transcription with cell cycle progression. , 1994, Current opinion in cell biology.
[30] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] A. Okamoto,et al. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. , 1996, International journal of cancer.
[32] K. Parang,et al. Current targets for anticancer drug discovery. , 2003, Current drug targets.
[33] H. Friess,et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] L. Neckers,et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.
[35] F. Salvi,et al. Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. , 2000, International journal of radiation oncology, biology, physics.
[36] K. Yanagisawa,et al. Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers , 2000, Oncogene.
[37] H. Koeffler,et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. , 2001, Cancer research.
[38] A. Papavassiliou,et al. Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas , 2002, The Journal of pathology.
[39] C. Heldin,et al. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.
[40] C. Croce,et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. , 1995, Cancer research.
[41] Q. Xue,et al. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung , 2002, Pathology international.
[42] E. Liu,et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents , 2001, Oncogene.
[43] A. Giordano,et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. , 1998, American journal of respiratory cell and molecular biology.
[44] S. Irniger. Cyclin destruction in mitosis: a crucial task of Cdc20 , 2002, FEBS letters.
[45] J. Kofron,et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. , 2003, Science.
[46] R. Makuch,et al. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. , 1987, The Journal of clinical investigation.
[47] E. Brambilla,et al. Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors , 2002, Oncogene.
[48] M. Volm,et al. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. , 1997, British Journal of Cancer.
[49] Scott E. Kern,et al. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.
[50] V. N. Nguyen,et al. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. , 2000, Acta histochemica.
[51] P. Zhou,et al. UV-damaged DNA-binding Proteins Are Targets of CUL-4A-mediated Ubiquitination and Degradation* , 2001, The Journal of Biological Chemistry.
[52] A. Miyauchi,et al. Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. , 2002, International journal of molecular medicine.
[53] J. Bartek,et al. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression , 1996, Molecular and cellular biology.
[54] J. Bartek,et al. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.
[55] T. Huang,et al. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. , 1997, Cancer research.
[56] J. Battey,et al. Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. , 1986, Cold Spring Harbor Symposia on Quantitative Biology.
[57] S. Miyoshi,et al. Disruption of the RB pathway and cell‐proliferative activity in non‐small‐cell lung cancers , 1998, International journal of cancer.
[58] E. Brambilla,et al. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. , 1998, Cancer research.
[59] S. Jiang,et al. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. , 1998, The American journal of pathology.
[60] Wei Zhang,et al. Interaction of CR6 (GADD45γ) with Proliferating Cell Nuclear Antigen Impedes Negative Growth Control* , 2001, The Journal of Biological Chemistry.
[61] Y. Yatabe,et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] H. Sasaki,et al. Expression of the Prothymosin-α Gene as a Prognostic Factor in Lung Cancer , 2001, Surgery Today.
[63] G E Moore,et al. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. , 1991, Cancer research.
[64] W. Kuo,et al. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. , 1998, Cancer research.
[65] K. Vareli,et al. Nuclear distribution of prothymosin alpha and parathymosin: evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication. , 2000, Experimental cell research.
[66] G. Hannon,et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.
[67] G. Jianhua,et al. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. , 1998, Cancer letters.
[68] A. Gartel,et al. p21—Negative Regulator of the Cell Cycle , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[69] W. Benedict,et al. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[70] J. Battey,et al. Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer. , 1984, Current topics in microbiology and immunology.
[71] F. Khuri,et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. , 2000, Cancer research.
[72] Dong Hoon Kim,et al. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. , 2003, Journal of biochemistry and molecular biology.
[73] T. Kameya,et al. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas , 2003, The Journal of pathology.
[74] Gregory R. Grant,et al. Generation of patterns from gene expression data by assigning confidence to differentially expressed genes , 2000, Bioinform..
[75] Carl W. Miller,et al. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors , 2002, Genes, chromosomes & cancer.
[76] C. Mathew,et al. The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. , 1999, Genomics.
[77] H. Sasaki,et al. Elevated plasma thymosin-alpha1 levels in lung cancer patients. , 1997, European Journal of Cardio-Thoracic Surgery.
[78] Carl W. Miller,et al. Molecular analysis of a family of cyclin‐dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non‐small cell lung cancers , 1995, Molecular carcinogenesis.
[79] É. Szabó,et al. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[80] L. Mao,et al. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. , 1998, Cancer research.
[81] C. W. Lee,et al. Functional interaction between DP-1 and p53 , 1996, Molecular and cellular biology.
[82] Scott E. Kern,et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.
[83] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[84] S. Elledge,et al. Human cyclin F. , 1994, The EMBO journal.